Scheduled for 13 weeks, the trial will assess the therapy’s safety, tolerability, and efficacy in weight loss.

Some of the best possible returns for investors come by not going after megacaps, but instead pursuing stocks that have more ...

2025年1月8日，Viking ...

JPMorgan keeps an Overweight rating and $80 price target on Viking Therapeutics (VKTX) after the company announced that it ...

Viking Therapeutics (VKTX) has received a new Buy rating, initiated by Stifel Nicolaus analyst, Annabel Samimy.Stay Ahead of the ...

In a rare move, the FDA recommended a minimum of 5% weight-loss for drug developers seeking to establish the efficacy of ...

Viking Therapeutics (VKTX) announced the initiation of a Phase 2 clinical trial of the oral tablet formulation of VK2735, the company’s dual ...

圣地亚哥 - Viking Therapeutics, Inc. (NASDAQ: VKTX)过去一年股价上涨了令人印象深刻的114%，该公司已经启动了VK2735的二期临床试验，这是一种旨在治疗肥胖症和相关代谢疾病的口服药物。根据 InvestingPro ...

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the ...

圣地亚哥—根据最近的SEC文件显示，Viking Therapeutics, Inc. (NASDAQ:VKTX)的首席财务官Zante Greg最近出售了公司大量股票。Greg于2025年1月6日在两笔独立交易中共售出50,309股。这些股票的售价在42.6888美元至43.3194美元之间，总计约215万美元。此次交易发生之际，Viking的股票交易价格高于其 InvestingPro ...

对于生物科技公司Viking Therapeutics（VKTX）来说，2024年是个极好的年份。因出色的中期临床结果，这家中型生物科技公司股票在2月份暴涨。尽管股价已从年初创下的历史高点下跌，但在过去12个月中，它仍然是行业内表现较好的公司之一。

Seeking Alpha analyst Terry Chrisomalis regards Viking Therapeutics as the most attractive M&A candidate in 2025, bolstered ...